Systemic delivery of nanoparticles, coated with autoimmune disease-relevant peptides bound to MHC class II molecules, promoted the in vivo generation and expansion of antigen-specific FOXP3-CD49b+LAG-3+ Treg cells in different humanized mouse models, including NSG mice reconstituted with T1D patient-derived CD8+ T cell-depleted PBMCs, and ameliorated clinical and pathological signs of CIA and experimental autoimmune encephalomyelitis in HLA-DR4-IE Tg mice (285). This evidence concerns the gene CD8A and type 1 diabetes mellitus.